Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Dr.Reddy'S Laboratories Ltd, also popularly known as Dr Reddy's, is a listed public company incorporated on 24 February, 1984. It is classified as a public limited company and is located in Hyderabad, Telangana. It's authorized share capital is INR 145.00 cr and the total paid-up capital is INR 83.44 cr.
Dr.Reddy'S Laboratories Ltd's operating revenue range is Over INR 500 cr for the financial year ending on 31 March, 2024. It's EBITDA has increased by 40.61% over the previous year. At the same time, it's book networth has increased by 18.4%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
14.86%
40.61%
66.18%
18.4%
118233.33%
19.64%
4.03
5.57
6.46
5.15
4.65
0.03
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(71)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
GLOBALTRUST BANK LTD
No. of Loans: 2
Total Amount : 20.0 cr
GLOBAL TRUST BANK LTD
No. of Loans: 2
Total Amount : 7.6 cr
GLOBAL TUST BANK LTD
No. of Loans: 1
Total Amount : 5.5 cr
IFCI Limited
No. of Loans: 1
Total Amount : 0.5 cr
Andhra Bank
No. of Loans: 2
Total Amount : 0.2 cr
DCL FINANCE LIMITED
No. of Loans: 4
Total Amount : 0.2 cr
NEW INDIA ASSURANCE COMPANY LTD
No. of Loans: 1
Total Amount : 0.1 cr
ANDHRA PRADESH STATE FINANCIAL CORP.
No. of Loans: 1
Total Amount : 0.0 cr
GENERAL INSURANCE CORPORATION OF INDIA
No. of Loans: 1
Total Amount : 0.0 cr
DCL FINANCE LTD
No. of Loans: 1
Total Amount : 0.0 cr
DCL FINANCE LTD.
No. of Loans: 1
Total Amount : 0.0 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Shikha Sanjaya Sharma | 00043265 | 6 years |
| Managing Director | Venkateswara Prasad Gunupati | 00057433 | 11 years |
| Whole-time Director | Satish Reddy Kallam
Shareholder
|
00129701 | 32 years |
| Director | Kodumudi Pranatharthiharan Krishnan | 01099097 | 3 years |
| Director | Alpna Hansraj Seth | 01183914 | 1 years |
| Director | Leo Puri | 01764813 | 6 years |
| Kmp | Mannam Venkata Narasimham | <HIDDEN> | 0 years |
| Director | Sanjiv Soshil Mehta | 06699923 | 1 years |
| CEO | Erez Israeli | <HIDDEN> | 5 years |
| Director | Penny Chan Wan | 09479493 | 3 years |
| Director | Arun Madhavan Kumar | 09665138 | 2 years |
| Director | Claudio Dr. Albrecht | 10109819 | 2 years |
| CS | Kumar Randhir Singh | <HIDDEN> | 3 years |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Dr. Reddy's Venezuela, C.A. | Venezuela, Bolivarian Republic Of | - | - |
| OctoPlus B.V. | Netherlands | - | - |
| Dr. Reddy’s Laboratories SAS | Colombia | - | - |
| Reddy Pharma Italia SPA | Italy | - | - |
| Reddy Pharma SAS | France | - | - |
| DR. REDDY'S BIO-SCIENCES LIMITED | Telangana | 2000 | ₹ 64.8 Cr |
| Chirotech Technology Limited | United Kingdom | - | - |
| Dr. Reddy’s Laboratories (UK) Limited | United Kingdom | - | - |
| Dr. Reddy's Laboratories Tennessee, LLC | United States | - | - |
| Euro Bridge Consulting B.V. | Netherlands | - | - |
| beta Institut gemeinn tzige GmbH, Germany | Germany | - | - |
| OctoPlus Technologies B.V. | Netherlands | - | - |
| Dr. Reddy’s Laboratories Japan KK | Japan | - | - |
| Dr. Reddy’s Laboratories (Australia) Pty. Limited | Australia | - | - |
| betapharm Arzneimittel GmbH | Germany | - | - |
| Dr. Reddy's New Zealand Limited | New Zealand | - | - |
| Reddy Netherlands B.V. | Netherlands | - | - |
| Dr. Reddy’s Laboratories Romania SRL | Romania | - | - |
| AURIGENE ONCOLOGY LIMITED | Karnataka | 2001 | ₹ 187.6 Cr |
| Chienna B.V. | Netherlands | - | - |
| OOO Dr. Reddy’s Laboratories Limited | Russian Federation | - | - |
| Reddy Antilles N.V. | Netherlands | - | - |
| Aurigene Discovery Technologies Inc. | United States | - | - |
| Dr. Reddy's Laboratories Canada Inc. | Canada | - | - |
| Dr. Reddy's Laboratories, LLC, Ukraine | Ukraine | - | - |
| Reddy Specialities GmbH | Germany | - | - |
| Dr. Reddy's Laboratories New York, Inc. | United States | - | - |
| IDEA2ENTERPRISES (INDIA) PRIVATE LIMITED | Telangana | 2000 | ₹ 2.5 Cr |
| OOO DRS LLC | Russian Federation | - | - |
| Reddy Cheminor S.A. | France | - | - |
| Dr. Reddy’s Laboratories SA | Switzerland | - | - |
| OctoShare B.V. | Netherlands | - | - |
| Dr. Reddy’s Laboratories (EU) Limited | United Kingdom | - | - |
| OctoPlus PolyActive Sciences B.V. | Netherlands | - | - |
| Kunshan Rotam Reddy Pharmaceutical Co. Limited | China | - | - |
| Reddy Pharma Iberia SA | Spain | - | - |
| Dr. Reddy’s Farmaceutica Do Brasil Ltda. | Brazil | - | - |
| Dr. Reddy’s SRL | Italy | - | - |
| Dr. Reddy’s Laboratories Inc. | United States | - | - |
| OctoPlus Sciences B.V. | Netherlands | - | - |
| DRL IMPEX LIMITED | Telangana | 1986 | ₹ 76.0 Cr |
| Reddy Holding GmbH | Germany | - | - |
| Lacock Holdings Ltd | Cyprus | - | - |
| Dr. Reddy’s Laboratories International SA | Switzerland | - | - |
| Aurigene Discovery Technologies (Malaysia) SDN BHD | Malaysia | - | - |
| DR.REDDY'S PHARMA SEZ LIMITED | India | - | - |
| OctoPlus Development B.V. | Netherlands | - | - |
| Industrias Quimicas Falcon de Mexico, S.A. | Mexico | - | - |
| Promius Pharma LLC | United States | - | - |
| Dr. Reddy’s Laboratories Louisiana LLC | United States | - | - |
| CHEMINOR INVESTMENTS LTD | Telangana | 1990 | ₹ 13.5 L |
| Dr. Reddy’s Laboratories (Proprietary) Limited | South Africa | - | - |
| Dr. Reddy’s Singapore PTE LTD | Singapore | - | - |
The incorporation date of DR.REDDY'S LABORATORIES LTD is 24 February, 1984
The authorized share capital of DR.REDDY'S LABORATORIES LTD is INR ₹ 145.0 Cr.
The paid-up capital of DR.REDDY'S LABORATORIES LTD is INR ₹ 83.4 Cr.
The registered address of DR.REDDY'S LABORATORIES LTD is 8-2-337, Road No. 3, Banjara Hills, NA Hyderabad Hyderabad Telangana - 500034
The CIN number of DR.REDDY'S LABORATORIES LTD is L85195TG1984PLC004507.
Expand
Delete
Collapse
See
details
It will take sometime. Please come back in 10
minutes
